|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:administered_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
|
gptkbp:can_be_combined_with
|
chemotherapy
targeted therapy
|
|
gptkbp:chemical_formula
|
C6424 H9924 N1716 O1980 S44
|
|
gptkbp:class
|
immune checkpoint inhibitor
|
|
gptkbp:clinical_trial
|
Phase III
|
|
gptkbp:clinical_use
|
first-line therapy
second-line therapy
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
gptkb:Software_Solutions
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atezolizumab
|
|
gptkbp:indication
|
gptkb:Oncology
gptkb:triple-negative_breast_cancer
urothelial carcinoma
|
|
gptkbp:invention
|
patented
|
|
gptkbp:marketed_as
|
gptkb:Tecentriq
|
|
gptkbp:mechanism_of_action
|
inhibits PD-L1
|
|
gptkbp:research
|
combination therapy
adjuvant therapy
neoadjuvant therapy
|
|
gptkbp:route_of_administration
|
IV
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
immune-related adverse events
|
|
gptkbp:targets
|
gptkb:Waldenström's_macroglobulinemia
gptkb:primary_mediastinal_B-cell_lymphoma
gptkb:disease
gptkb:PD-L1
gptkb:chronic_myeloid_leukemia
gptkb:myelodysplastic_syndromes
gptkb:hepatocellular_carcinoma
gptkb:Oncology
gptkb:non-Hodgkin_lymphoma
gptkb:pancreatic_cancer
gptkb:cervical_cancer
ovarian cancer
esophageal cancer
small cell lung cancer
bladder cancer
head and neck cancer
neuroendocrine tumors
thymic carcinoma
|
|
gptkbp:used_for
|
treatment of cancer
|
|
gptkbp:weight
|
146 k Da
|
|
gptkbp:bfsParent
|
gptkb:EMD_Serono
|
|
gptkbp:bfsLayer
|
5
|